000279477 001__ 279477
000279477 005__ 20250710100950.0
000279477 037__ $$aDZNE-2025-00804
000279477 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000279477 245__ $$aDataset: Secretomics of ADAM17 and iRhom2 KO BV2 cells using high-performance secretome protein enrichment with click sugars
000279477 260__ $$bPRoteomics IDEntifications Database$$c2025
000279477 3367_ $$2BibTeX$$aMISC
000279477 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1752049576_17545
000279477 3367_ $$026$$2EndNote$$aChart or Table
000279477 3367_ $$2DataCite$$aDataset
000279477 3367_ $$2ORCID$$aDATA_SET
000279477 3367_ $$2DINI$$aResearchData
000279477 520__ $$aThe cell surface receptor TREM2 is a key genetic risk factor and drug target in Alzheimer’s disease (AD). In the brain, TREM2 is expressed in microglia, where it undergoes proteolytic cleavage, linked to AD risk, but the responsible protease in microglia is unknown. Another microglia-expressed AD risk factor is inactive rhomboid 2 (iRhom2, RHBDF2), which acts as a non-catalytic subunit of the metalloprotease ADAM17. Its function in AD is unknown. To determine whether loss of iRhom2 and ADAM17 leads to a reduction of cleavage of additional membrane proteins beyond TNF, we used the ‘high-performance secretome protein enrichment with click sugars’ (hiSPECS) method for mass spectrometry-based secretome analysis (Tüshaus et al, 2020). hiSPECS uses a metabolic labeling with click sugars, which allows to culture cells in the presence of serum or serum-like supplements. Therefore, we have used the murine microglia cell line BV2 and introduced CRISPR/Cas9-mediated knockouts of RHBDF2/iRhom2 and ADAM17.
000279477 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000279477 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000279477 7870_ $$0DZNE-2025-00430$$aJocher, Georg et.al.$$dHeidelberg : EMBO Press, 2025$$iRelatedTo$$r$$tThe late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis
000279477 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD054894
000279477 909CO $$ooai:pub.dzne.de:279477$$pVDB
000279477 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000279477 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000279477 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000279477 9141_ $$y2025
000279477 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000279477 980__ $$adataset
000279477 980__ $$aVDB
000279477 980__ $$aI:(DE-2719)1110006
000279477 980__ $$aUNRESTRICTED